Publication at Second Faculty of Medicine |
2019
Abstract
The treatment of haemophilia A has undergone significant development over the last decade. In addition to standard treatment with clotting factor VIII concentrates, so-called non-factorial products are being tested in clinical trials and some of them have already been introduced to the clinical practice.
The first agent, called emicizumab, was recently approved for the Czech market. Emicizumab is a bispecific antibody that partially replaces function of the missing factor VIII as a cofactor and restores hemostatic potential of persons with haemophilia A.
Emicizumab is currently being administered to haemophiliacs A, whose treatment has been complicated by the development of inhibitors and whose immunotolerance treatment has failed.